Sernova Biotherapeutics (SVA) Q2 2025 earnings summary

Executive summary

• Report covers three and six months ended April 30, 2025, for a clinical-stage biotech focused on regenerative medicine and cell therapy for chronic diseases.

• Name changed to Sernova Biotherapeutics Inc. effective February 4, 2025.

• Operations span Canada and the US, with shares listed on multiple exchanges.

Financial highlights

• Net loss for six months ended April 30, 2025: $9.47M, improved from $19.69M loss in prior year period.

• Cash at April 30, 2025: $2.0M, down from $6.0M at October 31, 2024.

• Working capital deficit at April 30, 2025: $20.4M, including $12.7M in arrears to a vendor.

• Negative cash flow from operations for six months: $8.66M (2024: $11.49M).

• Weighted average shares outstanding for six months: 327.97M.

Outlook and guidance

• Material uncertainty exists regarding ability to continue as a going concern; additional funding required before end of June 2025.

• Strategic financing initiatives planned, including equity, loans, or alliances.

• Expects further losses as development and commercialization of Cell Pouch platform continues.